News | Stents | September 23, 2015

FDA OKs Second Randomized Trial for COBRA PzF Coronary Stent System

Second study will evaluate device’s ability to shorten dual antiplatelet therapy in patients at high risk of bleeding after PCI

CeloNova BioSciences, Cobra PzF coronary stent system, second randomized trial, COBRA-REDUCE

Cobra PzF coronary stent system image courtesy of CeloNova BioSciences Inc.

September 23, 2015 — CeloNova BioSciences Inc. announced that it has received conditional approval to start an investigational device exemption (IDE) trial to study the Cobra PzF coronary stent system in patients at high risk of bleeding. This is a second major interventional cardiology trial for CeloNova in the United States, following the successful enrollment of the PzF SHIELD clinical trial earlier this year.

This multicenter, prospective, randomized trial will be referred to as the COBRA-REDUCE trial. Prof. Adnan Kastrati, M.D., professor of medicine at ISAR Research Center, Munich, Germany, is the trial’s principal investigator.

The trial will evaluate if the Cobra PzF coronary stent, with its novel Polyzene-F nano-coating and advanced thin-strut design, can help reduce bleeding as compared to drug-eluting stents by shortening the duration of dual antiplatelet therapy (DAPT) to 14 days in patients treated with oral anticoagulation and undergoing percutaneous coronary intervention (PCI).

In February this year, CeloNova announced accelerated enrollment completion of its PzF SHIELD IDE trial, which will support regulatory submission for U.S. Food and Drug Administration (FDA) approval of the Cobra PzF stent.

The Cobra PzF coronary stent system received CE Mark approval in 2012 and launched in Europe and the Middle East in 2013.

For more information: www.celonova.com

Related Content

Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
Overlay Init